These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 22543217)

  • 1. Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer.
    Koay EJ; Lege D; Mohan R; Komaki R; Cox JD; Chang JY
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1093-100. PubMed ID: 22543217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adaptive carbon ion radiotherapy for locally advanced non-small cell lung cancer: Organ-sparing potential and target coverage.
    Jia S; Chen J; Ma N; Zhao J; Mao J; Jiang G; Lu J; Wu K
    Med Phys; 2022 Jun; 49(6):3980-3989. PubMed ID: 35192194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer.
    Chang JY; Komaki R; Wen HY; De Gracia B; Bluett JB; McAleer MF; Swisher SG; Gillin M; Mohan R; Cox JD
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1350-7. PubMed ID: 21251767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study.
    Zhang X; Li Y; Pan X; Xiaoqiang L; Mohan R; Komaki R; Cox JD; Chang JY
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):357-66. PubMed ID: 19660879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adapt-On-Demand: A Novel Strategy for Personalized Adaptive Radiation Therapy for Locally Advanced Lung Cancer.
    Li R; Zhuang T; Montalvo S; Wang K; Parsons D; Zhang Y; Iyengar P; Wang J; Godley A; Cai B; Lin MH; Westover K
    Pract Radiat Oncol; 2024; 14(5):e395-e406. PubMed ID: 38579986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of adaptive radiotherapy to escalate the radiation dose in combined radiochemotherapy for locally advanced non-small cell lung cancer.
    Guckenberger M; Wilbert J; Richter A; Baier K; Flentje M
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):901-8. PubMed ID: 20708850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of non-small cell lung cancer patients with proton beam-based stereotactic body radiotherapy: dosimetric comparison with photon plans highlights importance of range uncertainty.
    Seco J; Panahandeh HR; Westover K; Adams J; Willers H
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):354-61. PubMed ID: 21985941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
    Rwigema JM; Verma V; Lin L; Berman AT; Levin WP; Evans TL; Aggarwal C; Rengan R; Langer C; Cohen RB; Simone CB
    Cancer; 2017 Nov; 123(21):4244-4251. PubMed ID: 28678434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4π noncoplanar stereotactic body radiation therapy for centrally located or larger lung tumors.
    Dong P; Lee P; Ruan D; Long T; Romeijn E; Low DA; Kupelian P; Abraham J; Yang Y; Sheng K
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):407-13. PubMed ID: 23523322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of induction chemotherapy on the dosimetric parameters of subsequent radiotherapy: an investigation of 30 consecutive patients with locally-advanced non-small cell lung cancer and modern radiation planning techniques.
    Grant JD; Sobremonte A; Hillebrandt E; Allen PK; Gomez DR
    Radiat Oncol; 2015 Jan; 10():32. PubMed ID: 25636372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer.
    Register SP; Zhang X; Mohan R; Chang JY
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1015-22. PubMed ID: 20615629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.
    Rosenman JG; Halle JS; Socinski MA; Deschesne K; Moore DT; Johnson H; Fraser R; Morris DE
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):348-56. PubMed ID: 12243807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-criteria optimization achieves superior normal tissue sparing in a planning study of intensity-modulated radiation therapy for RTOG 1308-eligible non-small cell lung cancer patients.
    Kamran SC; Mueller BS; Paetzold P; Dunlap J; Niemierko A; Bortfeld T; Willers H; Craft D
    Radiother Oncol; 2016 Mar; 118(3):515-20. PubMed ID: 26830694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mid-position treatment strategy for locally advanced lung cancer: a dosimetric study.
    Ayadi M; Baudier T; Bouilhol G; Dupuis P; Boissard P; Pinho R; Krason A; Rit S; Claude L; Sarrut D
    Br J Radiol; 2020 Jun; 93(1110):20190692. PubMed ID: 32293191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity-modulated radiotherapy for locally advanced non-small-cell lung cancer: a dose-escalation planning study.
    Lievens Y; Nulens A; Gaber MA; Defraene G; De Wever W; Stroobants S; Van den Heuvel F;
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):306-13. PubMed ID: 20888706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer.
    Gomez DR; Gillin M; Liao Z; Wei C; Lin SH; Swanick C; Alvarado T; Komaki R; Cox JD; Chang JY
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):665-70. PubMed ID: 23688815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accumulation of the delivered dose based on cone-beam CT and deformable image registration for non-small cell lung cancer treated with hypofractionated radiotherapy.
    Wang B; Wang DQ; Lin MS; Lu SP; Zhang J; Chen L; Li QW; Cheng ZK; Liu FJ; Guo JY; Liu H; Qiu B
    BMC Cancer; 2020 Nov; 20(1):1112. PubMed ID: 33198676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Wang J; Xia TY; Wang YJ; Li HQ; Li P; Wang JD; Chang DS; Liu LY; Di YP; Wang X; Wu WZ
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e59-65. PubMed ID: 21345607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes.
    McAvoy S; Ciura K; Wei C; Rineer J; Liao Z; Chang JY; Palmer MB; Cox JD; Komaki R; Gomez DR
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):819-27. PubMed ID: 25220718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.